HCW Biologics announced it has regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by the Nasdaq Hearings Panel on June 29, 2026. To ensure long-term compliance, the company will also effect a one-for-six reverse stock split.

Key Details

  • Compliance Event: The company regained compliance with Nasdaq Listing Rule 5550(a)(2), the "Bid Price Rule."
  • Reverse Stock Split: A 1-for-6 reverse stock split will be effected on June 30, 2026, to maintain the required bid price.
  • Monitoring Period: The company is now subject to a mandatory monitoring period by the Nasdaq Panel through June 17, 2027.